Nurix Therapeutics (NRIX) Competitors $12.44 -0.23 (-1.82%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$12.54 +0.10 (+0.80%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRIX vs. RARE, AAPG, MRUS, ACLX, SWTX, RNA, ACAD, SRRK, VKTX, and PTGXShould you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), Scholar Rock (SRRK), Viking Therapeutics (VKTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Nurix Therapeutics vs. Its Competitors Ultragenyx Pharmaceutical Ascentage Pharma Group International Merus Arcellx SpringWorks Therapeutics Avidity Biosciences ACADIA Pharmaceuticals Scholar Rock Viking Therapeutics Protagonist Therapeutics Nurix Therapeutics (NASDAQ:NRIX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Which has better earnings and valuation, NRIX or RARE? Nurix Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$54.55M17.43-$193.57M-$2.61-4.77Ultragenyx Pharmaceutical$560.23M4.98-$569.18M-$5.88-5.02 Does the media prefer NRIX or RARE? In the previous week, Ultragenyx Pharmaceutical had 10 more articles in the media than Nurix Therapeutics. MarketBeat recorded 33 mentions for Ultragenyx Pharmaceutical and 23 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.31 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 5 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 10 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer NRIX or RARE? Nurix Therapeutics presently has a consensus target price of $29.59, indicating a potential upside of 137.85%. Ultragenyx Pharmaceutical has a consensus target price of $85.36, indicating a potential upside of 189.25%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.83Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Is NRIX or RARE more profitable? Ultragenyx Pharmaceutical has a net margin of -93.04% compared to Nurix Therapeutics' net margin of -234.57%. Nurix Therapeutics' return on equity of -45.26% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-234.57% -45.26% -34.71% Ultragenyx Pharmaceutical -93.04%-186.49%-36.81% Which has more volatility and risk, NRIX or RARE? Nurix Therapeutics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Do institutionals and insiders believe in NRIX or RARE? 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 7.4% of Nurix Therapeutics shares are held by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryNurix Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks. Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRIX vs. The Competition Export to ExcelMetricNurix TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$951.04M$2.94B$5.55B$9.09BDividend YieldN/A2.45%5.07%4.03%P/E Ratio-4.7720.8528.2520.32Price / Sales17.43291.87431.56110.05Price / CashN/A41.0526.2427.98Price / Book1.677.638.125.50Net Income-$193.57M-$55.05M$3.19B$250.38M7 Day Performance0.65%7.11%3.68%2.19%1 Month Performance4.27%8.14%7.70%10.92%1 Year Performance-47.77%1.62%29.39%16.41% Nurix Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRIXNurix Therapeutics1.5597 of 5 stars$12.44-1.8%$29.59+137.8%-47.8%$951.04M$54.55M-4.77300Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownRAREUltragenyx Pharmaceutical3.932 of 5 stars$39.61-0.8%$87.00+119.6%-34.6%$3.77B$560.23M0.001,294Trending NewsAnalyst ForecastAnalyst RevisionAAPGAscentage Pharma Group InternationalN/A$42.04-1.9%N/AN/A$3.73B$134.35M0.00600Gap DownMRUSMerus1.9089 of 5 stars$52.58-2.3%$84.64+61.0%-4.8%$3.73B$36.13M0.0037News CoverageAnalyst UpgradeInsider TradeACLXArcellx2.5494 of 5 stars$65.55-2.4%$111.23+69.7%+10.5%$3.70B$107.94M0.0080Positive NewsSWTXSpringWorks Therapeutics1.5709 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230RNAAvidity Biosciences2.1789 of 5 stars$28.80-1.3%$65.59+127.7%-29.8%$3.52B$10.90M0.00190News CoverageAnalyst UpgradeACADACADIA Pharmaceuticals4.6461 of 5 stars$20.88-0.3%$27.88+33.5%+18.1%$3.51B$957.80M15.24510Positive NewsAnalyst RevisionSRRKScholar Rock3.7261 of 5 stars$35.48-1.4%$42.67+20.3%+311.4%$3.42B$33.19M0.00140Insider TradeVKTXViking Therapeutics4.5833 of 5 stars$27.51-2.4%$87.15+216.8%-45.6%$3.17BN/A0.0020Positive NewsPTGXProtagonist Therapeutics1.5797 of 5 stars$49.87-2.3%$66.10+32.5%+46.7%$3.16B$434.43M68.07120Positive News Related Companies and Tools Related Companies RARE Alternatives AAPG Alternatives MRUS Alternatives ACLX Alternatives SWTX Alternatives RNA Alternatives ACAD Alternatives SRRK Alternatives VKTX Alternatives PTGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRIX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
